Industrial biotech specialist Ingenza is delighted to announce that it is collaborating with clinical-stage biopharmaceutical company Amplifica Holdings Group, Inc. to develop an innovative treatment to address androgenic alopecia. Amplifica has partnered with Ingenza to advance the development of its signalling molecules – which stimulate dormant hair follicle stem cells and result in the active regrowth of hairs – from proof of concept through toxicology and clinical trials. The project will capitalise on Ingenza’s microbial strain and mammalian-cell line development capabilities and demonstrates the company’s world-leading expertise in engineering biology.
Dr Ian Fotheringham, Managing Director at Ingenza, commented: “We look forward to partnering with Amplifica and sharing our expertise and knowledge to help advance both the lead product candidates and alternative versions with improved potential. Our innovative bio-manufacturing technologies and technical capabilities are a perfect fit with Amplifica’s expertise in developing novel therapeutics for hair regrowth.”
Frank Fazio, President and CEO at Amplifica added: “Our collaboration with Ingenza represents an opportunity to advance the development of first-in-class therapies for hair loss, a condition with a significant unmet need. We are excited to be using our understanding of hair biology to advance our proprietary pipeline products with the help of Ingenza’s team of experts.”